Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 EPS estimates for Ionis Pharmaceuticals in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($3.44) per share for the year, down from their prior estimate of ($3.41). HC Wainwright has a "Buy" rating and a $70.00 price objective on the stock. The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals' Q4 2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($1.09) EPS, Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.10) EPS and FY2027 earnings at ($1.94) EPS.
A number of other analysts have also weighed in on the stock. UBS Group began coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, October 15th. They set a "buy" rating and a $88.00 price objective for the company. Citigroup restated a "buy" rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 21st. Oppenheimer lowered their price objective on Ionis Pharmaceuticals from $85.00 to $70.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 10th. Wall Street Zen raised Ionis Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 14th. Finally, Weiss Ratings lowered Ionis Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday. Nineteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $75.00.
Read Our Latest Research Report on IONS
Ionis Pharmaceuticals Trading Down 0.7%
NASDAQ IONS opened at $27.21 on Friday. Ionis Pharmaceuticals has a 12 month low of $26.55 and a 12 month high of $86.74. The company has a current ratio of 5.43, a quick ratio of 5.36 and a debt-to-equity ratio of 3.42. The stock's fifty day moving average price is $41.31 and its 200-day moving average price is $63.46. The stock has a market cap of $4.53 billion, a P/E ratio of -8.20 and a beta of 0.43.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The firm had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. During the same period last year, the business earned ($0.80) earnings per share. The business's revenue was up 54.8% on a year-over-year basis.
Hedge Funds Weigh In On Ionis Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in IONS. Alyeska Investment Group L.P. raised its position in Ionis Pharmaceuticals by 199.7% during the second quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company's stock valued at $112,427,000 after purchasing an additional 944,766 shares during the period. Bank of America Corp DE bought a new position in shares of Ionis Pharmaceuticals during the 2nd quarter valued at approximately $62,718,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Ionis Pharmaceuticals during the second quarter worth $54,253,000. TimesSquare Capital Management LLC purchased a new position in Ionis Pharmaceuticals during the second quarter worth $48,690,000. Finally, GW&K Investment Management LLC boosted its stake in Ionis Pharmaceuticals by 79.6% during the third quarter. GW&K Investment Management LLC now owns 1,341,315 shares of the company's stock worth $59,890,000 after buying an additional 594,349 shares during the period. 93.86% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Ionis Pharmaceuticals
In other news, EVP Shannon Devers sold 1,357 shares of the business's stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $43.54, for a total value of $59,083.78. Following the transaction, the executive vice president directly owned 17,811 shares in the company, valued at $775,490.94. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Hayden bought 5,000 shares of the business's stock in a transaction that occurred on Tuesday, November 10th. The shares were acquired at an average price of $29.64 per share, with a total value of $148,200.00. Following the transaction, the director directly owned 27,000 shares of the company's stock, valued at $800,280. This represents a 22.73% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.81% of the stock is owned by company insiders.
About Ionis Pharmaceuticals
(
Get Free Report)
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company's research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.